Omnicell (NASDAQ:OMCL) Given New $58.00 Price Target at Barclays

Omnicell (NASDAQ:OMCL) had its target price upped by Barclays from $39.00 to $58.00 in a report released on Thursday, Benzinga reports. The brokerage currently has an equal weight rating on the stock.

OMCL has been the subject of a number of other reports. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 19th. Benchmark restated a “buy” rating and issued a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Wells Fargo & Company lifted their price target on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. JPMorgan Chase & Co. upped their price objective on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Finally, Craig Hallum lifted their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Omnicell has an average rating of “Hold” and an average price target of $49.14.

Omnicell Price Performance

Omnicell stock opened at $48.67 on Thursday. The company has a fifty day simple moving average of $43.34 and a 200-day simple moving average of $35.38. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of -124.79, a PEG ratio of 53.62 and a beta of 0.81. The company has a quick ratio of 2.22, a current ratio of 1.05 and a debt-to-equity ratio of 0.47. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. The company had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. During the same quarter in the prior year, the company earned $0.29 EPS. Omnicell’s revenue was down 7.4% compared to the same quarter last year. On average, equities analysts anticipate that Omnicell will post 0.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its position in shares of Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after buying an additional 1,000 shares during the period. 1620 Investment Advisors Inc. grew its stake in shares of Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after buying an additional 1,542 shares in the last quarter. EntryPoint Capital LLC raised its holdings in shares of Omnicell by 121.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after buying an additional 1,345 shares during the period. Finally, CWM LLC lifted its stake in Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after acquiring an additional 1,236 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.